Experiences with
Biologic Therapy10,000 public posts
2025 Spring -Information only - NHS England notification of contingent liability - COVID-19 spring 2025 vaccination programme
Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide
Want to take advantage of all our features? Just log in!
or
The Benefits of Physical, Speech, and Occupational Therapies - The Motivator
This issue’s cover story, “The Benefits of Physical, Speech, and Occupational Therapies,” takes a deeper look into therapy options for those living with MS, as well as the potential benefits one may experience.